Evidence map›Paper›PMID 39917037›Full record

ArticleToxicology reports2025

Acute and prolonged toxicity assessment of

Alana C Costa, Arquimedes Gasparotto, Alana A K Garcia, Cícero A C Pereira, Emerson L B Lourenço, Helena P G Joaquim

Abstract read
In one paragraph

Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Acute and Subchronic Exposure to Hemp (Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alana C CostaGreenCare Pharma, Vinhedo, SP, Brazil.
Arquimedes GasparottoLaboratory of Electrophysiology and Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS, Brazil.
Alana A K GarciaLaboratory of Pharmacology and Toxicology of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Cícero A C PereiraGreenCare Pharma, Vinhedo, SP, Brazil.
Emerson L B LourençoLaboratory of Pharmacology and Toxicology of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Helena P G JoaquimGreenCare Pharma, Vinhedo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabinoids offer a novel pharmacotherapeutic approach and can complement other medications to address unmet clinical needs in numerous patients, which has led to a global increase in the use of these products. No significant safety concerns have been identified in preclinical studies involving CBD and THC. However, the available data on the toxicity of combined CBD and THC are still inconclusive. Evaluating full-spectrum

Indexed as

CannabinoidsCannabisSafetyToxicity

Identifiers

PMID39917037
PMCPMC11800086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.